May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
Evaluation of Clinical Effects of a Purified High–Dose Anthocyanoside Oligomer
Author Affiliations & Notes
  • J. Lee
    Department of Ophthalmology, Institute of Vision Research, Yonsei Univ. Yongdong severance hopital, Seoul, Republic of Korea
  • G. Seong
    Department of Ophthalmology, Institute of Vision Research, Yonsei Univ. Yongdong severance hopital, Seoul, Republic of Korea
  • S. Kim
    Department of Ophthalmology, Institute of Vision Research, Yonsei Univ. Yongdong severance hopital, Seoul, Republic of Korea
  • S. Han
    Department of Ophthalmology, Institute of Vision Research, Yonsei Univ. Yongdong severance hopital, Seoul, Republic of Korea
  • H. Lee
    Department of Ophthalmology, Institute of Vision Research, Yonsei Univ. Yongdong severance hopital, Seoul, Republic of Korea
  • O. Kwon
    Department of Ophthalmology, Institute of Vision Research, Yonsei Univ. Shinchon severance hopital, Seoul, Republic of Korea
  • Footnotes
    Commercial Relationships  J. Lee, None; G. Seong, None; S. Kim, None; S. Han, None; H. Lee, None; O. Kwon, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 5624. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. Lee, G. Seong, S. Kim, S. Han, H. Lee, O. Kwon; Evaluation of Clinical Effects of a Purified High–Dose Anthocyanoside Oligomer . Invest. Ophthalmol. Vis. Sci. 2005;46(13):5624.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To evaluate the benefit of taking purified high–dose anthocyanoside oligomer for improving nocturnal visual function and clinical symptoms. Methods: We performed a randomized, double–blind, placebo–controlled trial in low to moderate myopia subjects. The subjects who were included in this study had a refractive error with asthenopia between –1.00 and –8.00 diopters in both eyes. A total of 60 people who qualified the criteria above were enrolled and the subjects were instructed to take purified high–dose anthocyanoside oligomer or placebo twice daily for a period of 4 weeks. Age, refractive error, and morphoscopic contrast sensitivity (MCS) were matched between placebo group and treatment group. The enrolled subjects were investigated for nocturnal vision performance by MCS and clinical symptoms at their first visit and re–evaluated at post–intervention (unpaired t–test and Fisher's exact test) Results: Four weeks after the study, 22 subjects (73.3%) of anthocyanoside group showed symptomatic improvement compared to the subjects of placebo group (p=0.000). Contrast sensitivity levels, according to each cycles/degree (CPD) before and after drug taking, were also significantly improved in anthocyanoside group. The mean MCS change of anthocyanoside group was 2.41±1.91, compared to –0.40±2.47 of the placebo group (p=0.000). In all levels of CPD, MCS changes in anthocyanoside group showed significant improvement compared to the placebo group (p<0.05). Conclusions: Our results show that purified high–dose anthocyanoside oligomer may improve the subjective symptoms and objective MCS results in myopia subjects with asthenopia.

Keywords: contrast sensitivity • myopia 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×